费城染色体在混合表型急性白血病中的预后影响:一项基于癌症登记的真实世界结局分析
基于监测、流行病学和最终结果登记库中241例按2008年WHO分类的混合表型急性白血病(MPAL)病例,分析不同亚型结局。多因素校正年龄、诊断年份和化疗状态后,费城染色体阳性(Ph+)MPAL患者死亡风险低于Ph阴性患者(HR=0.28,P=.002),MLL+亚型预后最差(HR=10.2,P<.001),Ph+ MPAL结局与Ph+急性淋巴细胞白血病在1:1匹配病例对照分析中相当。
要点
- Ph+ MPAL患者死亡风险较Ph阴性患者降低(HR=0.28,P=.002)。
- MLL+ MPAL预后最差,死亡风险为Ph+ MPAL的10.2倍(P<.001)。
- Ph+ MPAL结局与Ph+急性淋巴细胞白血病在1:1匹配分析中相当。
核心结论
- MPAL是异质性疾病,Ph+ MPAL当前总生存优于其他亚型,与Ph+急性淋巴细胞白血病相当,可能继发于实践变化和酪氨酸激酶抑制剂使用增加。
- MLL重排与婴儿型MPAL相关且预后极差。
研究设计与样本
- 基于监测、流行病学和最终结果登记库的登记研究,纳入241例按2008年WHO分类的MPAL病例。
- 采用多因素分析,校正年龄、诊断年份和化疗状态。
- 进行1:1匹配病例对照分析比较Ph+ MPAL与Ph+急性淋巴细胞白血病。
主要发现
- MLL+患者中位年龄6岁,其他亚型主要发生于成人且年龄相当。
- 多因素校正后,Ph+ MPAL患者死亡风险低于Ph阴性MPAL患者(HR=0.28,P=.002)。
- MLL+ MPAL死亡风险为Ph+ MPAL患者的10.2倍(HR=10.2,P<.001)。
- 1:1匹配病例对照分析中,Ph+ MPAL结局与Ph+急性淋巴细胞白血病相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mixed phenotype acute leukemia (MPAL) is thought to have poor outcome, and presence of the Philadelphia chromosome (Ph+) has been considered to be an adverse prognostic marker. However, most of these reports were in the pre-tyrosine kinase inhibitors (TKIs) era. Recent limited reports indicate improved outcomes for MPAL with the addition of TKIs. We examined the outcomes of 241 cases of MPAL according to the 2008 WHO classification from the Surveillance, Epidemiology, and End Results registry. The MLL+ patients had a median age of 6 years while other subtypes occurred mostly in adults and had comparable age. On multivariate analyses and after adjustment for age, year of diagnosis and chemotherapy status, Ph+ MPAL patients had reduced risk of death in comparison to Ph(-) MPAL patients (hazard ratio [HR] = 0.28, P = .002). So, MLL+ MPAL had the worst outcome with a 10-fold increased risk of death in comparison to Ph+ MPAL patients (HR = 10.2, P < .001). Importantly, the outcome of Ph+ MPAL was comparable to Ph+ acute lymphoblastic leukemia in a 1:1 matched case-control analysis. In conclusion, this is the largest registry study which examines the outcomes of MPAL subtypes. We confirm that MPAL is a heterogenous disease. Note, Ph+ MPAL nowadays has a better OS in comparison to other subtypes and is comparable to Ph+ ALL patients. This is most likely secondary to changes in practice and more utilization of TKIs. On the other hand, MLL rearrangement is associated with infantile MPAL and has a dismal prognosis.
引用
- Qasrawi A, Ramlal R, Munker R, et al. Prognostic impact of Philadelphia chromosome in mixed phenotype acute leukemia (MPAL): A cancer registry analysis on real-world outcome. Am J Hematol. 2020. PMID: 32419244. doi:10.1002/ajh.25873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。